What antidepressant is safe for a breastfeeding mother, including recommended dose, dosing frequency, and common maternal side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antidepressant Safe for Breastfeeding

Sertraline and paroxetine are the preferred first-line antidepressants for breastfeeding mothers, with sertraline starting at 25-50 mg daily (can titrate to 50-200 mg daily) and paroxetine starting at 10-20 mg daily (can titrate to 20-50 mg daily), both taken once daily.

Preferred Agents: Sertraline and Paroxetine

These two selective serotonin reuptake inhibitors (SSRIs) consistently demonstrate the best safety profile during breastfeeding across multiple studies 1, 2, 3, 4, 5.

Why These Are Safest:

  • Minimal infant exposure: Both produce very low or undetectable plasma concentrations in nursing infants 2
  • Relative infant dose (RID) <1%: The amount transferred through breast milk is negligible 1
  • No adverse events reported: Unlike fluoxetine and citalopram, there are no documented adverse effects in breastfed infants exposed to sertraline or paroxetine 4, 5

Dosing Recommendations

Sertraline

  • Starting dose: 25-50 mg orally once daily
  • Maintenance dose: 50-200 mg daily
  • Frequency: Once daily (typically in morning)

Paroxetine

  • Starting dose: 10-20 mg orally once daily
  • Maintenance dose: 20-50 mg daily
  • Frequency: Once daily (typically in morning)

Common Maternal Side Effects

Both medications share similar side effect profiles:

  • Gastrointestinal: Nausea, diarrhea, dry mouth (most common initially)
  • Central nervous system: Headache, insomnia or drowsiness, dizziness
  • Sexual dysfunction: Decreased libido, delayed orgasm
  • Other: Sweating, fatigue, weight changes

Important caveat: Paroxetine has a shorter half-life and may cause more withdrawal symptoms if doses are missed, requiring consistent daily administration.

Agents to Use With Caution

Bupropion can be considered as an alternative, particularly if the mother was already taking it during pregnancy 6. However, caution is advised:

  • Present in breast milk at very low levels 6
  • Two case reports of seizures in breastfed infants exist 6
  • Dosing if used: SR formulation 100-150 mg twice daily, or XL formulation 150-300 mg once daily

Agents to Avoid

  • Fluoxetine and citalopram: Associated with higher infant plasma levels and suspected adverse effects in some infants 2, 4
  • Atomoxetine: No published breastfeeding studies; effects on nursing infants unknown 6
  • MAOIs: Should generally be avoided 1

Clinical Implementation

Monitor the infant for:

  • Adequate weight gain
  • Normal sleep patterns
  • Appropriate developmental milestones
  • Any signs of irritability, poor feeding, or sedation

Timing strategy: If using any antidepressant, consider timing breastfeeding or pumping to coincide with the lowest drug concentration in milk (typically just before the next dose).

The evidence strongly supports that breastfeeding and antidepressant treatment are not mutually exclusive 3. The benefits of treating maternal depression and continuing breastfeeding both outweigh the minimal risks associated with sertraline or paroxetine exposure 2, 5.

References

Research

Antidepressant Medication Use During Lactation: A Review for Providers.

South Dakota medicine : the journal of the South Dakota State Medical Association, 2024

Research

Antidepressant Use During Breastfeeding.

Current women's health reviews, 2011

Research

Antidepressant medication use during breastfeeding.

Clinical obstetrics and gynecology, 2009

Research

[Antidepressant drugs and breastfeeding].

Recenti progressi in medicina, 2007

Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.